Evidence map›Paper›PMID 36263045›Full record

ArticleFrontiers in immunology2022

Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202.

Tsung-Po Lai, Simon Verhulst, Casey L Dagnall, Amy Hutchinson, Stephen R Spellman, Alan Howard, Hormuzd A Katki, John E Levine, Wael Saber, Abraham Aviv and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Tsung-Po LaiCenter of Human Development and Aging, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, United States.
Simon VerhulstGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands.
Casey L DagnallDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Amy HutchinsonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Stephen R SpellmanCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN, United States.
Alan HowardCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN, United States.
Hormuzd A KatkiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
John E LevineTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Wael SaberCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States.
Abraham AvivCenter of Human Development and Aging, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, United States.
Shahinaz M GadallaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Frederick National Laboratory for Cancer Research · USNational Marrow Donor Program · USRutgers, The State University of New Jersey · USDivision of Cancer Epidemiology and GeneticsIcahn School of Medicine at Mount Sinai · USMedical College of Wisconsin · USNational Cancer Institute · USUniversity of Groningen · NL

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
Institutional Career Development CoreKL2TR003018 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI CHAN, JOHN R., HALM, ETHAN A · 2019 to 2023
$3.0M
Telomere Length Measurements: Strengths and LimitationsU01AG066529 · NIA · RBHS-NEW JERSEY MEDICAL SCHOOL · PI AVIV, ABRAHAM · 2019 to 2021
$911k
NCATS NIH HHS KL2 TR003018NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NIA NIH HHS U01 AG066529
6 · The paper itself

Abstract

The age of allogeneic hematopoietic cell transplant (HCT) donors and their hematopoietic cell telomere length (TL) might affect recipients' outcomes. Our goals were to examine the possible effect of these donors' factors on the recipients' hematopoietic cell TL and quantify hematopoietic cell TL shortening in the critical first three-month post-HCT. We measured hematopoietic cell TL parameters in 75 recipient-donor pairs, from the Blood and Marrow Transplant Clinical Trials Network (protocol#1202), by Southern blotting (SB), the Telomeres Shortest Length Assay (TeSLA), and quantitative PCR (qPCR). Recipients' hematopoietic cell TL parameters post-HCT correlated with donors' age (p<0.001 for all methods), but not recipients' own age, and with donors' pre-HCT hematopoietic cell TL (p<0.0001 for all). Multivariate analyses showed that donors' hematopoietic cell TL pre-HCT, independent of donors' age, explained most of the variability in recipients' hematopoietic cell TL post-HCT (81% for SB, 56% for TeSLA, and 65% for qPCR; p>0.0001 for all). SB and TeSLA detected hematopoietic cell TL shortening in all recipients post-HCT (mean=0.52kb and 0.47kb, respectively; >15-fold the annual TL shortening in adults; p<0.00001 for both), but qPCR detected shortening only in 57.5% of recipients. TeSLA detected a buildup of post-HCT of telomeres <3 kb in 96% of recipients (p<0.0001). In conclusion, HCT decouples hematopoietic cell TL in the recipients from their own age to reflect the donors' age. The potential donors' age effect on outcomes of HCT might be partially mediated by short hematopoietic cell TL in older donors. qPCR-based TL measurement is suboptimal for detecting telomere shortening post-HCT.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantsAdultAgedHumansTelomereTissue Donorsagingallogeneic hematopoietic cell transplantdonor selectiontelomere length assaytelomere length dynamicstelomere length (TL)

Identifiers

PMID36263045
PMCPMC9574912
OpenAlexW4300960583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.